The University of Nottingham's School of Chemistry, in collaboration with AstraZeneca, is offering three fully funded 48-month PhD studentships focused on the sustainable synthesis of peptide and oligonucleotide therapeutics. These projects integrate cutting-edge research in machine learning, photocatalysis, and chemoenzymatic synthesis, aiming to advance the development of next-generation therapeutics. The positions are ideal for candidates with a strong background in chemistry, chemical biology, or related fields, and an interest in interdisciplinary research that bridges computational and experimental approaches. The studentships are supported by AstraZeneca, ensuring robust funding for tuition and living expenses. Applicants are encouraged to review detailed project descriptions on the CDT website and apply before the extended deadline of January 2, 2026. This is an excellent opportunity to join a leading research group at the University of Nottingham and contribute to impactful research in sustainable therapeutic synthesis.